5MJC MDS/AML 6: A Prognostic Model for MDS that Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)
A Prognostic Model for MDS that Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS) 5MJC MDS/AML 9: Three Alternate Dosing Schedules of Azacitidine for MDS
Three Alternate Dosing Schedules of Azacitidine for MDS 5MJC MDS/AML 8: EORTC-06011: Low-Dose Decitabine versus Best Supportive Care for Elderly Patients with Intermediate- or High-Risk MDS
EORTC-06011: Low-Dose Decitabine versus Best Supportive Care for Elderly Patients with Intermediate- or High-Risk MDS 5MJC MDS/AML 7: Azacitidine Before Allogeneic Hematopoietic Cell Transplantation (AHCT) for Myelodysplasias
Azacitidine Before Allogeneic Hematopoietic Cell Transplantation (AHCT) for Myelodysplasias 5MJC MDS/AML 4: Anthracycline Dose Intensification in Acute Myeloid Leukemia (AML)
Anthracycline Dose Intensification in Acute Myeloid Leukemia (AML) 5MJC MDS/AML 3: Outcome of Myelodysplastic Syndrome (MDS) with and without Chromosome 5 Abnormalities
Outcome of Myelodysplastic Syndrome (MDS) with and without 5MJC MDS/AML 2: Efficacy of Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS)
Efficacy of Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) 5MJC MDS/AML 1: Cooked and Noncooked Diets in Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy
Cooked and Noncooked Diets in Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy 5MJC RCCU 4: Pazopanib in Patients with Treatment-Naïve or Cytokine-Pretreated Advanced RCC
Pazopanib in Patients with Treatment-Naïve or Cytokine-Pretreated Advanced RCC 5MJC RCCU 3: Sunitinib Continuous 37.5 mg/Day Dosing in Cytokine-Refractory Metastatic RCC
Sunitinib Continuous 37.5 mg/Day Dosing in Cytokine-Refractory Metastatic RCC 5MJC RCCU 2: Everolimus in Patients with Cytokine-Pretreated mRCC
Everolimus in Patients with Cytokine-Pretreated mRCC 5MJC RCCU 1: Presurgical Feasibility of Bevacizumab for Nephrectomy-Eligible, Treatment-Naïve Patients with Metastatic Renal Cell Carcinoma
Presurgical Feasibility of Bevacizumab for Nephrectomy-Eligible, Treatment-Naïve Patients with Metastatic Renal Cell Carcinoma Subscription | Sign up to receive your complimentary copy of Breast Cancer Update Think TankIf you would like to to receive immediate notification and a link to download our Breast Cancer Update Think Tank program when it’s available online, or to receive the program by mail in hard copy with audio CDs†, please take a moment to fill out the brief form below and indicate your preference of email, hard copy or both. †Hard copy by mail currently available to practicing US clinicians only. * This field is required. Subscription | Sign up to receive your complimentary copy of Renal Cell Think TankIf you would like to to receive immediate notification and a link to download our Renal Cell Think Tank program when it’s available online, or to receive the program by mail in hard copy with audio CDs†, please take a moment to fill out the brief form below and indicate your preference of email, hard copy or both. †Hard copy by mail currently available to practicing US clinicians only. * This field is required.  |